EUGIT THERAPEUTICS, INC.

Biotech · Private

A platform for identifying and developing targeted delivery agents that accumulate in diseased tissues, initially focused on gastrointestinal tract localization for IBD treatment.

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Tissue specific delivery of payloads$275,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1105Vault Nano Inc——
1106Pretzel Therapeutics——
1107VAXNEWMO, LLC——
1108EUGIT THERAPEUTICS, INC.——
1109Proximity Biosciences LLC——
1110EMMUNE INC——
1111EPPIN PHARMA, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Targeting Payloadsapplication
  • Targeting Payloadsapplication
  • Targeting Payloadsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.